Introduction {#s1}
============

The world is currently going through an unprecedented pandemic of the coronavirus disease 2019 (COVID-19) that has now affected millions of people \[[@R01]\]. Compared to seasonal influenza, COVID-19 is more contagious, has a longer incubation period, and is associated with higher hospitalization and mortality rates \[[@R02]-[@R04]\]. The clinical presentation varies from no symptoms to acute respiratory failure, shock, and multi-organ system dysfunction \[[@R02]\]. Those with older ages, male gender, obesity, and chronic comorbidities such as cardiovascular disease, diabetes, chronic respiratory disease, and cancer were more likely to have worse outcomes \[[@R02], [@R05], [@R06]\]. Patients with COVID-19 present with multiple hematological abnormalities, of which lymphopenia and thrombocytopenia were prominent. Acute phase reactants like C-reactive protein, lactate dehydrogenase, ferritin, and D-dimer have also been well correlated with disease severity and progression \[[@R07]\].

Inflammation plays a major role in the pathophysiology of COVID-19. Both the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) indirectly reflect a patient's inflammatory state. The NLR is calculated as the absolute neutrophil count divided by the absolute lymphocyte count, while the PLR is calculated by platelet count divided by absolute lymphocyte count. In the recent years, NLR and PLR have been validated as prognostic markers in various disorders such as cardiac conditions, solid tumors, sepsis, pneumonia, and acute respiratory distress syndrome (ARDS) \[[@R08]-[@R13]\]. Few studies have evaluated the role of NLR and PLR in patients with severe and non-severe COVID-19. We performed this meta-analysis to identify the association of NLR and PLR in relation to the severity of COVID-19.

Materials and Methods {#s2}
=====================

We performed a literature search using EMBASE, MEDLINE, and Google Scholar for studies reporting the use of NLR and PLR in COVID-19 published until April 28, 2020. We used the medical subject headings (MESH) terms: "neutrophil-to-lymphocyte ratio," "platelet-to-lymphocyte ratio," "NLR", "PLR," "COVID-19," "novel coronavirus", and "SARS-CoV-2." Inclusion criteria were: 1) Descriptive studies comparing between severe versus non-severe, or survivor versus deaths in COVID-19 patients; 2) Non-pregnant adult patients; 3) Studies reporting NLR or PLR values. Eligible studies were reviewed, and data including study design, sample size, baseline characteristics, NLR, and PLR values were obtained. Definitions of COVID-19 disease severity were based on individual studies.

This meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@R13]\]. We used the Cochrane Review Manager version 5.3 for our analysis. Mean and standard deviation were extrapolated from median and interquartile range (IQR) using the method outlined by Hozo et al \[[@R14]\]. For each outcome, standard mean difference and 95% confidence interval (CI) were calculated using the random effects model utilizing the inverse variance method. A P value of 0.05 or less was assigned as the measure of statistical significance. Study heterogeneity was assessed by calculating I^2^ statistics; heterogeneity was considered significant if I^2^ \> 50%.

Results {#s3}
=======

The initial search yielded a total of 403 studies, of which 20 studies were included in the final analysis ([Fig. 1](#F1){ref-type="fig"}) \[[@R15]-[@R34]\]. All studies were conducted in China. A total of 3,508 patients, with 946 in severe COVID-19 group and 2,561 in non-severe, were included. Clinical demographics are outlined in [Table 1](#T1){ref-type="table"} \[[@R15]-[@R34]\]. The criteria for severe and non-severe disease varied between each study, but most studies considered respiratory distress and care in intensive units as severe disease. Study specific definitions are listed here ([Supplementary Material 1](#S1){ref-type="supplementary-material"}, [www.jocmr.org](http://www.jocmr.org)).

![PRISMA diagram. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](jocmr-12-448-g001){#F1}

###### Clinical Characteristics of Included Studies

  Study                          Baseline characteristics   Number of patients   Study design           Age, mean/median   Female, n (%)   Comorbidities                                                                         
  ------------------------------ -------------------------- -------------------- ---------------------- ------------------ --------------- --------------- ----------- ----------- ---------- ----------- ----------- ---------- ---------
  Qin et al, 2020 \[[@R15]\]     Non-severe                 166                  Retrospective review   53                 86 (51.8)       3 (1.8)         30 (18.1)   3 (1.8)     3 (1.8)    3 (1.8)     22 (13.3)   4 (2.4)    4 (2.4)
  Severe                         286                                             53                     131 (45.8)         9 (3.1)         105 (36.7)      24 (8.4)    8 (2.8)     3 (1.0)    53 (18.5)   10 (3.5)    6 (2.1)    
  Liu et al, 2020 \[[@R16]\]     Non-severe                 44                   Prospective review     41                 23 (52.3)       2 (4.5)         6 (13.6)    0 (0)       \-         \-          2 (4.5)     \-         \-
  Severe                         17                                              56                     7 (41.2)           3 (17.6)        6 (35.3)        1 (5.9)     \-          \-         3 (17.6)    \-          \-         
  Yang et al, 2020 \[[@R17]\]    Non-severe                 69                   Retrospective review   42.1               31 (44.9)       \-              7 (10.1)    4 (5.8)     \-         9 (13.0)    8 (11.6)               2 (2.9)
  Severe                         24                                              57.9                   6 (25)             \-              16 (66.8)       9 (37.5)    \-          4 (16.7)   13 (54.2)               8 (33.3)   
  Xia et al, 2020 \[[@R18]\]     Non-severe                 7                    Case series            54                 2 (28.6)        \-              1 (14)      \-          \-         1 (14)      \-          \-         \-
  Severe                         3                                               61.6                   2 (66.7)           \-              \-              \-          \-          \-         \-          \-          \-         
  Zhang et al, 2020 \[[@R19]\]   Non-severe                 81                   Retrospective review   59.3               42 (52.8)       \-              \-          \-          \-         \-          \-          \-         \-
  Severe                         67                                              60.8                   29 (43.3)          \-              \-              \-          \-          \-         \-          \-          \-         
  Qu et al, 2020 \[[@R20]\]      Non-severe                 27                   Case series            49.4               \-              \-              \-          \-          \-         \-          \-          \-         \-
  Severe                         3                                               60                     \-                 \-              \-              \-          \-          \-         \-          \-          \-         
  Ye et al, 2020 \[[@R21]\]      Survivor                   297                  Retrospective review   60                 160 (53.9)      \-              73 (24.6)   \-          \-         \-          41 (13.8)   \-         \-
  Non-survivor                   52                                              69                     16 (30.8)          \-              30 (57.7)       \-          \-          \-         16 (30.8)   \-          \-         
  Zhang et al, 2020 \[[@R22]\]   Non-severe                 84                   Retrospective review   44                 55 (65.5)       \-              \-          \-          \-         \-          \-          \-         \-
  Severe                         31                                              64.6                   11 (35.5)          \-              \-              \-          \-          \-         \-          \-          \-         
  Sun et al, 2020 \[[@R23]\]     Non-severe                 89                   Retrospective review   47                 47 (52.8)       \-              \-          \-          \-         \-          \-          \-         \-
  Severe                         27                                              62                     9 (33.3)           \-              \-              \-          \-          \-         \-          \-          \-         
  Song et al, 2020 \[[@R24]\]    Non-severe                 31                   Retrospective review   48                 30 (71.4)       1 (3.2)         4 (12.9)    1 (3.2)     \-         3 (9.7)     2 (6.5)     \-         \-
  Severe                         42                                              55.5                   12 (28.6)          2 (4.8)         22 (52.4)       4 (9.5)     \-          1 (2.4)    4 (9.5)     \-          \-         
  Gong et al, 2020 \[[@R25]\]    Non-severe                 161                  Retrospective review   45                 89 (55.3)       \-              \-          \-          \-         \-          \-          \-         \-
  Severe                         28                                              63.5                   12 (42.9)          \-              \-              \-          \-          \-         \-          \-          \-         
  Ma et al, 2020 \[[@R26]\]      Non-severe                 17                   Retrospective review   61                 7 (41.1)        \-              \-          \-          \-         \-          \-          17 (100)   \-
  Severe                         20                                              65.5                   10 (50)            \-              \-              \-          \-          \-         \-          20 (100)    \-         
  Wei et al, 2020 \[[@R27]\]     Non-severe                 137                  Did not mention        40.83              62 (45.3)       2 (1.5)         \-          17 (12.4)   2 (1.5)    \-          4 (2.9)     \-         \-
  Severe                         30                                              49.03                  10 (33.3)          2 (6.7)         \-              7 (23.3)    0           \-         7 (23.3)    \-          \-         
  Zhang et al, 2020 \[[@R28]\]   Recovered                  50                   Retrospective review   62.6               14 (28)         4 (8)           18 (36)     11 (22)     4 (8)                  5 (10)      \-         \-
  Death                          10                                              70.6                   3 (30)             2 (20)          4 (40)          3 (30)      2 (20)                 4 (40)      \-          \-         
  Zhu et al, 2020 \[[@R29]\]     Non-severe                 111                  Retrospective review   50                 38 (34.2)       4 (3.6)         23 (20.7)   4 (3.6)                5 (4.5)     10 (9)      4 (3.6)    \-
  Severe                         16                                              57.5                   7 (43.8)           2 (12.5)        8 (50)          2 (12.5)                2 (12.5)   0           1 (6.25)    \-         
  Zhang et al, 2020 \[[@R30]\]   Survivors                  268                  Case-control studies   56                 131 (48.9)      3 (1.12)        64 (23.9)   30 (11.2)   7 (2.6)    7 (2.6)     34 (12.7)   8 (3)      2 (0.8)
  Non-survivors                  47                                              66                     9 (19.1)           0               14 (29.8)       5 (10.6)    0           2 (4.3)    7 (14.9)    4 (8.5)     0          
  Liu et al, 2020 \[[@R31]\]     Non-severe                 43                   Retrospective review   55                 17 (39.5)       0               13 (30.2)   0           4 (9.3)    1 (2.3)     2 (4.7)     0          \-
  Severe                         79                                              65                     33 (41.8)          2 (2.5)         37 (46.8)       2 (2.5)     6 (7.6)     2 (2.5)    13 (16.5)   1 (1.3)     \-         
  Ma et al, 2020 \[[@R32]\]      Non-severe                 572                  Retrospective review   44                 273 (47.7)      \-              90 (15.7)   \-          \-         \-          29 (5.1)    \-         \-
  Severe                         63                                              53.3                   34 (54)            \-              15 (24)         \-          \-          \-         6 (10)      \-          \-         
  Cheng et al, 2020 \[[@R33]\]   Survivors                  67                   Retrospective review   70.6               45 (67.2)       7 (10.4)        39 (58.2)   11 (16.4)              1 (1.5)     11 (16.4)   2 (3)      3 (4.5)
  Non-survivors                  51                                              73.1                   20 (39.2)          6 (11.8)        25 (49)         12 (23.5)               0          16 (31.4)   0           3 (5.9)    
  Chen et al, 2020 \[[@R34]\]    Non-severe                 241                  Retrospective review   42.1               123             5 (2.1)         20 (8.3)    7 (3)       5 (2.1)    13 (5.4)    15 (6.2)    2 (0.8)    1 (0.4)
  Severe                         50                                              60.5                   23 (46)            5 (10)          19 (38)         5 (10)      3 (6)       2 (4)      7 (14)      0           1 (2)      

COPD: chronic obstructive pulmonary disease.

A total of 19 studies with 3,478 patients reported NLR values \[[@R15]-[@R19], [@R21]-[@R34]\]. Fifteen studies reported NLR between severe and non-severe disease, while four studies reported NLR based on survival. PLR was identified in five studies \[[@R17], [@R20], [@R23], [@R25], [@R29]\]. Patients with severe COVID-19 disease had higher NLR values (standard mean difference (SMD): 2.80, 95% CI: 2.12 - 3.48, P \< 0.00001) when compared to patients with non-severe disease ([Fig. 2](#F2){ref-type="fig"}). In the subgroup analysis, NLR values were higher in non-survivors when compared to survivors (SMD: 3.72, 95% CI: 0.53 - 6.90, P = 0.02) ([Supplementary Material 2](#S2){ref-type="supplementary-material"}, [www.jocmr.org](http://www.jocmr.org)). Similarly, PLR was elevated in patients with severe disease compared to non-severe disease (SMD: 1.82, 95% CI: 1.03 - 2.61, P \< 0.00001) ([Fig. 3](#F3){ref-type="fig"}). Significant heterogeneity was noted in the study results (I^2^ = 97% for NLR and I^2^ = 89% for PLR).

![NLR in severe versus non-severe COVID-19 patients. NLR: neutrophil-to-lymphocyte ratio; COVID-19: coronavirus disease 2019; SD: standard deviation; CI: confidence interval.](jocmr-12-448-g002){#F2}

![PLR in severe versus non-severe COVID-19 patients. PLR: platelet-to-lymphocyte ratio; COVID-19: coronavirus disease 2019; SD: standard deviation; CI: confidence interval.](jocmr-12-448-g003){#F3}

Discussion {#s4}
==========

Patients with severe COVID-19 disease had higher NLR and PLR values compared to non-severe disease. The present study shows that levels of NLR and PLR correlate with COVID-19 disease severity.

Patients with severe COVID-19 disease present with increased leukocytosis, neutrophilia, lymphopenia, and thrombocytopenia than those with non-severe disease \[[@R07]\]. These patients were more likely to develop ARDS and require intensive care unit (ICU) level of care \[[@R35]-[@R37]\]. NLR and PLR are easily obtained from a serum complete blood count with a differential profile. They serve as a function of relative neutrophilia, thrombocytosis, and lymphopenia. The different mechanisms of lymphopenia in COVID-19 patients have been linked to the virus's ability to infect T cells through the angiotensin-converting enzyme 2 (ACE2) receptors and cluster of differentiation (CD)147-spike proteins \[[@R38], [@R39]\]. The final results were decreased levels of CD3^+^, CD4^+^, CD8^+^ T lymphocytes, and increased regulatory T cells. The rise of proinflammatory cytokines with T cell lymphopenia predisposes severe COVID-19 patients to cytokine storm, thus resulting in more lymphocytic apoptosis and multi-organ failure. Overall, the decreased levels of CD4^+^ and CD8^+^ T lymphocytes correlated with disease severity, which can lead to increase NLR or PLR \[[@R02], [@R04], [@R15], [@R16]\].

In cases of other viral and bacterial pneumonia, NLR was more sensitive than individual levels of neutrophils and lymphocytes \[[@R40]\]. Similarly, PLR correlated well with mortality and disease severity in bacterial pneumonia \[[@R12], [@R41]\]. In the study by Liu et al, NLR was found to be the most prognostic among multiple variables in determining the severity of illness. Furthermore, when compared to other risk assessment tools such as CURB-65 and multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hypertension, and age (MuLBSTA), NLR had a higher sensitivity and specificity \[[@R16]\]. While many inflammatory markers like C-reactive protein, erythrocyte sedimentation rate, lactate dehydrogenase, ferritin, and procalcitonin are frequently measured in COVID-19 patients, NLR and PLR can be easily calculated using the differential count and are cost-effective especially for many third world countries. A previous meta-analysis composed of 828 patients and six studies concluded that a high NLR and low lymphocyte-to-C-reactive protein ratio indicated poor prognosis \[[@R42]\]. The previous study used mean or median values of neutrophils and lymphocytes from individual studies to calculate NLR. For this meta-analysis, we have chosen to exclude studies that did not have the calculated NLR values. Nevertheless, the results of this study were consistent with the previous meta-analysis and individual studies. So far, this is the first meta-analysis to evaluate the prognostic significance of PLR in COVID-19.

There are some limitations to the study. First of all, most of the studies are retrospective reviews, and all included studies were conducted in China. Second, heterogeneity exists between the included patient populations, with some studies not elucidating on underlying comorbidities. Third, it was unclear when in the disease course, the NLR and PLR values were measured. Depending on the severity of COVID-19, disease values of NLR and PLR will likely change.

Conclusions {#s4a}
-----------

This study establishes NLR and PLR as independent prognostic markers to differentiate severe versus non-severe disease in COVID-19 patients. Early recognition of the severe cases allows for early triaging and timely initiation of management. These markers are cost-effective and easily accessible in all laboratories. Future studies should compare the trends of NLR and PLR with disease progression.
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